Japanese BAY86-9766 Monotherapy Phase I Study
This is an uncontrolled, open-label, non-randomized phase I / pharmacokinetic study of oral BAY86-9766 to investigate the safety, tolerability, pharmacokinetics, and efficacy profiles in Japanese patients with advanced solid tumors
Neoplasms
DRUG: BAY86-9766|DRUG: BAY86-9766|DRUG: BAY86-9766|DRUG: BAY86-9766
Safety evaluation due to results of physical examinations, vital signs, AEs, abnormal laboratory tests and 12-lead ECG, cardiac function test and ophthalmological examination., At the end of 30-day follow up after discontinuation of study drug administration|Calculation of pharmacokinetic parameters of BAY86-9766 and its metabolite (M17)., Cycle 1 Day 22 and Day 23 for Cohorts 1 & 2 and Cohorts 3 & 4, respectively.
Response rate, On average 3 months|Disease control rate, On average 3 months
This is an uncontrolled, open-label, non-randomized phase I / pharmacokinetic study of oral BAY86-9766 to investigate the safety, tolerability, pharmacokinetics, and efficacy profiles in Japanese patients with advanced solid tumors